ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1028

ADAM-10 Plays Monocyte Migration and Adhesion in Rheumatoid Arthritis Synovial Fibroblasts

Takeo Isozaki1,2, Sho Ishii2, Shinichiro Nishimi2, Airi Maeoka2, Mayu Saito2, Nao Oguro2, Shinya Seki2, Yoko Miura2, Yusuke Miwa2, Koei Oh3, Yoichi Toyoshima3, Masanori Nakamura3, Katsunori Inagaki3 and Tsuyoshi Kasama2, 1Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, 3Department of Orthopedics, Showa University School of Med, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adhesion molecules, chemokines, cytokines, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose :A disintegrin and metalloprotease family proteins (ADAMs) have been reported to be involved in a number of inflammatory conditions. We previously reported that ADAM-10 mediated rheumatoid arthritis (RA) angiogenesis. In this study, we examine the expression of ADAM-10 in RA biological fluids and the role it plays in monocyte migration, cell adhesion, and proliferation.

Methods :ADAM-10 expression was determined in serum and synovial fluids (SFs) from normal (NL) subjects, osteoarthritis (OA) patients and RA patients using enzyme linked immunosorbent assay (ELISA). To determine expression of ADAM-10 on RA synovial fibroblasts, immunofluorescence was performed. To examine the role of ADAM-10 in RA synovial fluids (SFs), we performed THP-1 (human acute monocytic leukemia cell line) chemotaxis. To block the expression of ADAM-10, RA synovial fibroblasts were transfected with siRNA against ADAM-10. In order to determine that ADAM-10 mediates monocyte adhesion, ADAM-10 siRNA transfected RA synovial fibroblast adhesion assay was performed. To determine if ADAM-10 played a role in cell proliferation in the RA synovium, ADAM-10 siRNA-transfected RA synovial fibroblast proliferation assays were performed.

Results :The expression of ADAM-10 in RA serum was significantly higher compared to NL serum [mean ± SE; 450 ± 44 pg/ml (n=90) and 85 ± 33 pg/ml (n=34), respectively] and was correlated with a disease activity score of 28. ADAM-10 concentration in RA SFs was significantly elevated compared with that in OA SFs [(727 ± 144 pg/ml (n=10) and 255 ± 42 pg/ml (n=7), respectively]. ADAM-10 was expressed on RA synovial tissue lining cells and synovial fibroblasts. ADAM-10-depleted RA SFs showed a 56 ± 9% (n=5 patients) decrease in THP-1 migratory activity compared to sham-depleted controls. Adhesion of THP-1 to ADAM-10 siRNA-transfected RA synovial fibroblasts in response to tumor necrosis factor (TNF)-α was significantly decreased compared with control siRNA-transfected RA synovial fibroblasts. Finally, RA synovial fibroblasts transfected with ADAM-10 siRNA showed less proliferation in response to TNF-α at 2.5 ng/ml for 48 hours.

Conclusion :These data indicate that ADAM-10 plays a role in monocyte migration in RA and suggest that targeting ADAM-10 may provide a method by which to decrease inflammation and potentially treat other inflammatory diseases.


Disclosure:

T. Isozaki,
None;

S. Ishii,
None;

S. Nishimi,
None;

A. Maeoka,
None;

M. Saito,
None;

N. Oguro,
None;

S. Seki,
None;

Y. Miura,
None;

Y. Miwa,

Tanabe-Mitsubishi,

2,

Wyeth Pharmaceuticals,

2,

Chugai,

2,

Abbott Immunology Pharmaceuticals,

2,

Asteras,

2,

Ono,

2,

Bristol-Myers Squibb,

2;

K. Oh,
None;

Y. Toyoshima,
None;

M. Nakamura,
None;

K. Inagaki,
None;

T. Kasama,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adam-10-plays-monocyte-migration-and-adhesion-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology